{
  "abstract": "Background Hepatic arterial infusion chemotherapy (HAIC) is a potentially attractive locoregional therapy for patients with unresectable colorectal liver metastases (CRLM). This study aimed to evaluate the safety and efficacy of FOLFOX-HAIC plus regorafenib in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy. Methods A total of 35 patients with unresectable CRLM who underwent FOLFOX-HAIC plus regorafenib between July 2020 and January 2023 were included in this retrospective study. The objective response rate (ORR), disease-controlled rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse event were assessed. Factors affecting OS were analyzed. Results Kaplan–Meier curves showed that the median OS1 (measured from the time of diagnosis), OS2 (measured from the time of the first HAIC treatment) and PFS (measured from the time of the first HAIC treatment) were 29.0 (95%CI, 18.9–39.1) months, 21.0 (95%CI, 14.9–27.1) months and 13.0 (95%CI, 9.3–16.7) months, respectively. The ORRs at 3 months, 6 months and 12 months after HAIC were 57.1%, 45.7% and 22.9%, respectively, and the DCRs were 88.6%, 80.0% and 51.4%, respectively. No grade 5 adverse events (AEs) (death) were observed. Common Regorafenib-related AEs were hand-foot skin reaction (n = 18, 51.4%) and fatigue (n = 15, 42.9%). Common HAIC-related AEs were weight loss (n = 28, 80.0%), abdominal pain (n = 19, 54.3%) and nausea (n = 15, 42.9%). Conclusions FOLFOX-HAIC plus regorafenib might be beneficial and tolerable in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jiacheng Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Songlin Song"
    },
    {
      "affs": [
        0
      ],
      "name": "Wei Yao"
    },
    {
      "affs": [
        0
      ],
      "name": "Yanqiao Ren"
    },
    {
      "affs": [
        0
      ],
      "name": "Yiming Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Chuansheng Zheng"
    },
    {
      "affs": [
        0
      ],
      "name": "Bin Liang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ds8x84w1he5rx.bib",
  "cited_by": 0,
  "doi": "10.1186/s12885-026-16545-7",
  "fulltext_url": "https://doi.org/10.1186/s12885-026-16545-7",
  "id": "ds8x84w1he5rx",
  "issns": [
    "1471-2407"
  ],
  "landing_url": "https://doi.org/10.1186/s12885-026-16545-7",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Colorectal Cancer Treatments and Studies"
    ]
  ],
  "openalex": "W7168236624",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-07-01",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/ds8x84w1he5rx.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:46:05Z",
      "native_id": "c22457fc8d914f58a938e4ab3fb3bc5d",
      "source": "doaj",
      "url": "https://doi.org/10.1186/s12885-026-16545-7"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Colorectal Cancer Treatments and Studies",
      "subfield": "oncology"
    }
  ],
  "title": "FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy",
  "title_text": "FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:46:05Z",
  "url": "https://research.draconitic.com/paper/ds8x84w1he5rx",
  "venue": "BMC Cancer",
  "versions": []
}